SynthesisBrain and behavior2026
Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute ischemic stroke (AIS) is a leading cause of mortality and long-term disability worldwide. Despite advances in acute stroke management, many patients continue to experience substantial neurological disability and incomplete recovery. Minocycline, a tetracycline antibiotic with anti-inflammatory and neuroprotective properties and good blood-brain barrier penetration, has been investigated as a potential adjunctive therapy in AIS.
methodsA systematic search of major databases was conducted identifying randomized controlled trials evaluating minocycline in patients with AIS. Outcomes included functional and neurological recovery assessed using the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel index (BI), as well as mortality and vascular events. Pooled effect estimates were calculated using random-effects meta-analysis.
resultsSeven RCTs comprising 2197 patients were included, with 1093 receiving minocycline and 1104 receiving placebo or standard care. Functional independence at 3 months (mRS 0-2) showed no significant difference between groups (RR 1.28, 95% CI 0.97-1.69; I
conclusionsAlthough a consistent improvement in functional independence was not demonstrated, minocycline showed signals of benefit in selected neurological outcomes with a favorable safety profile. These findings support the need for adequately powered, multicenter randomized trials to clarify its therapeutic role.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.